Corcept Q1 revenue $157.2M (+7%); FY25 guide $900-950M reaffirmed; relacorilant & dazucorilant updates

CORCEPT THERAPEUTICS INC

2025-Q1 EPS reported $0.17 revenue$157,214,000

Revenue $157.2M, up 7% YoY; diluted EPS $0.17 vs $0.25; operating expenses rose to $153.8M from $117.3M.
Reiterated FY 2025 revenue guidance $900-950M; cash/investments $570.8M (down from $603.2M due to buybacks).
Relacorilant NDA for Cushing's under FDA review with PDUFA Dec 30, 2025; NDA for ovarian cancer expected Q3 2025.
Phase 3 ROSELLA trial met PFS and OS endpoints; results to be presented at ASCO June 2025.
Dazucorilant ALS trial missed primary endpoint; exploratory survival benefit at 1yr (HR 0.16, p=0.0009); seeking regulatory input.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.